Non-alcoholic Steatohepatitis

The Metabolic Syndrome

Volumn , Issue , 2006, Pages 279-303

  Ahmed, Mohamed Hassan ^a   Byrne, Christopher D ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

MRI in diagnosis of NASH; Non alcoholic fatty liver disease (NAFLD); Non alcoholic steatohepatitis (NASH); Non specific biochemical tests; Peroxisome proliferator activated receptor (PPAR) ; Peroxisome proliferator activated receptors (PPARs); Sterol regulatory element binding proteins (SREBPs); TNF gene in adipose tissue; UCP 2 gene expression in hepatocytes

Indexed keywords

EID: 84889850022     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470025131.ch11     Document Type: Chapter

References (140)

1. Abdelmalek, M. F., Angulo, P., Jorgensen, R. A., Sylvestre, P. B., Lindor, K. D. 2001. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol., 96 (9), 2711-2717.
2. Alba L. M., Lindor, K. 2003. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 17 (8), 977-986.
3. Andersen, T., Gluud, C., Franzmann, M. B., Christoffersen, P. 1991. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 12 (2), 224-229.
4. Angulo, P., 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med., 346 (16), 1221-1231.
5. Angulo, P., Lindor, K. D. 2002. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. Suppl, 17, S186-S190.
6. Angulo, P., Keach, J. C., Batts, K. P., Lindor, K. D. 1999. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 30 (6), 1356-1362.
7. Bacon, B. R., Farahvash, M. J., Janney, C. G., Neuschwander-Tetri, B. A. 1994. Nonalco-holicsteatohepatitis: an expanded clinical entity. Gastroenterology, 107 (4), 1103-1109.
8. Barak, A. J., Beckenhauer, H. C., Tuma, D. J. 1996. Betaine effects on hepatic methionine metabolism elicited by short-term ethanol feeding. Alcohol, 13 (5), 483-486.
9. Basaranoglu, M., Acbay, O., Sonsuz, A. 1999. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol., 31 (2), 384.
10. Becard, D., Hainault, I., Zzout-Marniche, D., Bertry-Coussot, L., Ferre, P., Foufelle, F. 2001. Adenovirus-mediated overexpression of sterol regulatory element binding protein-1c mimics insulin effects on hepatic gene expression and glucose homeostasis in diabetic mice. Diabetes, 50 (11), 2425-2430.
11. Bellentani, S., Tiribelli, C. 2001. The spectrum of liver disease in the general population: lesson from the Dionysos study. J. Hepatol., 35 (4), 531-537.
12. Berg, A. H., Combs, T. P., Scherer, P. E. 2002. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab., 13, (2), 84-89.
13. Bernal-Reyes, R., Escudero, R. B. 2000. Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Rev. Gastroenterol. Mex., 67, (2), 70-75.
14. Boden, G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 46, (1), 3-10.
15. Bonkovsky, H. L., Jawaid, Q., Tortorelli, K., LeClair, P., Cobb, J., Lambrecht, R. W., Banner, B. F. 1999. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J. Hepatol., 31, (3), 421-429.
16. Brunt, E. M. 2001. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis., 21, (1), 3-16.
17. Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., Sheppard, B. L. 2001. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 96, (2), 519-525.
18. Chakravarty, K., Leahy, P., Becard, D., Hakimi, P., Foretz, M., Ferre, P., Foufelle, F., Hanson, R. W. 2001. Sterol regulatory element-binding protein-1c mimics the negative effect of insulin on phosphoenolpyruvate carboxykinase (GTP) gene transcription. J. Biol. Chem., 276, (37), 34816-34823.
19. Chalasani, N., Gorski, J. C., Asghar, M. S., Asghar, A., Foresman, B., Hall, S. D., Crabb, D. W. 2003. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology, 37, (3), 544-550.
20. Chan, C. B., MacDonald, P. E., Saleh, M. C., Johns, D. C., Marban, E., Wheeler, M. B. 1999. Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes, 48, (7), 1482-1486.
21. Chen, Q., Galleano, M., Cederbaum, A. I. 1998. Cytotoxicity and apoptosis produced by arachidonic acid in HepG2 cells overexpressing human cytochrome P-4502E1. Alcohol Clin. Exp. Res., 22, (4), 782-784.
22. Chinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J. C., Chapman, J., Najib, J., Staels, B. 1998. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem, 273 (40), 25573-25580.
23. Chitturi, S., Farrell, G. C. 2001. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver. Dis, 21, (1), 27-41.
24. Clark, J. M., Brancati, F. L., Diehl, A. M. E. 2001. Non alcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population. Gastroenterology, 120 (Suppl. a-65).
25. Cohen, B., Novick, D., Rubinstein, M. 1996. Modulation of insulin activities by leptin. Science, 274 (5290), 1185-1188.
26. Cook, G. A., Gamble, M. S. 1987. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J. Biol. Chem, 262 (5), 2050-2055.
27. Cortez-Pinto, H., Yang, S. Q., Lin, H. Z., Costa, S., Hwang, C. S., Lane, M. D., Bagby, G., Diehl, A. M. 1998. Bacterial lipopolysaccharide induces uncoupling protein-2 expression in hepatocytes by a tumor necrosis factor-alpha-dependent mechanism. Biochem. Biophys. Res. Commun., 251 (1), 313-319.
28. Creutzfeldt, W., Mende, D., Willms, B., Soling, H. D. 1970. Vascular basement membrane thickness in muscle of spiny mice and activities of glycolysis and gluconeogenesis in the liver of animals with spontaneous and experimental diabetes and of untreated human diabetics. Diabetologia, 6 (3), 356-360.
29. de Marco, R., Locatelli, F., Zoppini, G., Verlato, G., Bonora, E., Muggeo, M. 1999. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care, 22 (5), 756-761.
30. Debaere, C., Rigauts, H., Laukens, P. 1998. Transient focal fatty liver infiltration mimicking liver metastasis. J. Belge Radiol., 81 (4), 174-175.
31. Deguti, M. M., Sipahi, A. M., Gayotto, L. C., Palacios, S. A., Bittencourt, P. L., Goldberg, A. C., Laudanna, A. A., Carrilho, F. J., Cancado, E. L. 2003. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz. J. Med. Biol. Res, 36 (6), 739-745.
32. Diehl, A. M. 2002. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol. Gastrointest. Liver Physiol., 282 (1), G1-G5.
33. Diehl, A. M., Goodman, Z., Ishak, K. G. 1988. Alcohol like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology, 95 (4), 1056-1062.
34. Drenick, E. J., Simmons, F., Murphy, J. F. 1970. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N. Engl. J. Med., 282 (15), 829-834.
35. el-Hassan, A. Y., Ibrahim, E. M., al-Mulhim, F. A., Nabhan, A. A., Chammas, M. Y. 1992. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br. J. Radiol., 65 (777), 774-778.
36. Emery, M. G., Fisher, J. M., Chien, J. Y., Kharasch, E. D., Dellinger, E. P., Kowdley, K. V., Thummel, K. E. 2003. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 38 (2), 428-435.
37. Facchini, F. S., Humphreys, M. H., DoNascimento, C. A., Abbasi, F., Reaven, G. M. 2000. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am. J. Clin. Nutr., 72 (3), 776-779.
38. Fiatarone, J. R., Coverdale, S. A., Batey, R. G., Farrell, G. C. 1991. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J. Gastroenterol. Hepatol., 6 (6), 585-590.
39. Franzese, A., Vajro, P., Argenziano, A., Puzziello, A., Iannucci, M. P., Saviano, M. C., Brunetti, F., Rubino, A. 1997. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig. Dis. Sci., 42 (7), 1428-1432.
40. Fruebis, J., Tsao, T. S., Javorschi, S., Ebbets-Reed, D., Erickson, M. R., Yen, F. T., Bihain, B. E., Lodish, H. F. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA, 98, (4), 2005-2010.
41. Gearing, K. L., Gottlicher, M., Widmark, E., Banner, C. D., Tollet, P., Stromstedt, M., Rafter, J. J., Berge, R. K., Gustafsson, J. A. 1994. Fatty acid activation of the peroxisome proliferator activated receptor, a member of the nuclear receptor gene superfamily. J. Nutr., 124, (8), 1284S-1288S.
42. George, D. K., Goldwurm, S., MacDonald, G. A., Cowley, L. L., Walker, N. I., Ward, P. J., Jazwinska, E. C., Powell, L. W. 1998. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 114 (2), 311-318.
43. Haque, M., Sanyal, A. J. 2002. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best. Pract. Res. Clin. Gastroenterol., 16 (5), 709-731.
44. Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., Terano, A. 2001. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther., 15 (10), 1667-1672.
45. Horton, J. D., Shimomura, I. 1999. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol., 10 (2), 143-150.
46. Horton, J. D., Bashmakov, Y., Shimomura, I., Shimano, H. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA., 95 (11), 5987-5992.
47. Hotamisligil, G. S., Spiegelman, B. M. 1994. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 43 (11), 1271-1278.
48. Hotamisligil, G. S., Johnson, R. S., Distel, R. J., Ellis, R., Papaioannou, V. E., Spiegelman, B. M. 1996a. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science, 274 (5291), 1377-1379.
49. Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., Spiegelman, B. M. 1996b. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science, 271 (5249), 665-668.
50. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., Nishida, M., Kihara, S., Sakai, N., Nakajima, T., Hasegawa, K., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Hanafusa, T., Matsuzawa, Y. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20 (6), 1595-1599.
51. Hotta, K., Funahashi, T., Bodkin, N. L., Ortmeyer, H. K., Arita, Y., Hansen, B. C., Matsuzawa, Y. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 50 (5), 1126-1133.
52. Howard, B. V. 1999. Insulin resistance and lipid metabolism. Am. J. Cardiol., 84 (1A), 28J-32J.
53. Isley, W. L. 2003. Hepatotoxicity of thiazolidinediones. Expert. Opin. Drug. Safety., 2 (6), 581-586.
54. Itoh, S., Yougel, T., Kawagoe, K. 1987. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am. J. Gastroenterol., 82 (7), 650-654.
55. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., Lemasters, J. J. 2002. Mechanisms of hepatotoxicity. Toxicol. Sci., 65 (2), 166-176.
56. James, O. F., Day, C. P. 1998. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol., 29 (3), 495-501.
57. Jiang, C., Ting, A. T., Seed, B. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391 (6662), 82-86.
58. Kessova, I., Cederbaum, A. I. 2003. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr. Mol. Med., 3 (6), 509-518.
59. Kim, J. B., Sarraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B. B., Spiegelman, B. M. 1998. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest., 101 (1), 1-9.
60. Kim, Y. M., Talanian, R. V., Billiar, T. R. 1997. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem, 272 (49), 31138-31148.
61. Kissebah, A. H., Krakower, G. R. 1994. Regional adiposity and morbidity. Physiol. Rev., 74 (4), 761-811.
62. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., Evans, R. M. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 91 (15), 7355-7359.
63. Kugelmas, M., Hill, D. B., Vivian, B., Marsano, L., McClain, C. J. 2003. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology, 38 (2), 413-419.
64. Kumar, K. S., Malet, P. F. 2000. Nonalcoholic steatohepatitis. Mayo Clin. Proc., 75 (7), 733-739.
65. Laurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., McGill, D. B. 1996. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology, 23 (6), 1464-1467.
66. Lavine, J. E. 2000. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr., 136 (6), 734-738.
67. Leclercq, I. A. 2004. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clin. Sci. (London), 106 (3), 235-237.
68. Lee, F. Y., Li, Y., Zhu, H., Yang, S., Lin, H. Z., Trush, M., Diehl, A. M. 1999. Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice liver. Hepatology, 29 (3), 677-687.
69. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., Gonzalez, F. J. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol., 15 (6), 3012-3022.
70. Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., Brown, M. S. 2002. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem., 277 (11), 9520-9528.
71. Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., Diehl, A. M. 2000. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med., 6 (9), 998-1003.
72. Lindor, K. D., Kowdley, K. V., Heathcote, E. J., Harrison, M. E., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., Colin, P. 2004. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 39 (3), 770-778.
73. Longo, R., Pollesello, P., Ricci, C., Masutti, F., Kvam, B. J., Bercich, L., Croce, L. S., Grigolato, P., Paoletti, S., de Bernard, B., 1995. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J. Magn. Reson. Imag., 5 (3), 281-285.
74. Lu, S. N., Wang, L. Y., Chang, W. Y., Chen, C. J., Su, W. P., Chen, S. C., Chuang, W. L., Hsieh, M. Y. 1990. Abdominal sonographic screening in a single community. Gaoxiong Yi Xue Ke Xue Za Zhi, 6 (12), 643-646.
75. Luyckx, F. H., Scheen, A. J., Lefebvre, P. J. 1999. Non-alcoholic steatohepatitis. Lancet, 354 (9186), 1298-1299.
76. Luyckx, F. H., Scheen, A. J., Desaive, C., Dewe, W., Gielen, J. E., Lefebvre, P. J. 1998. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab., 24 (4), 355-361.
77. Maddux, B. A., Sbraccia, P., Kumakura, S., Sasson, S., Youngren, J., Fisher, A., Spencer, S., Grupe, A., Henzel, W., Stewart, T. A., et al. 1995. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature, 373 (6513), 448-451.
78. Manes, J. L., Taylor, H. B., Starkloff, G. B. 1973. Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients. J. Clin. Pathol., 26 (10), 776-783.
79. Marceau, P., Biron, S., Hould, F. S., Marceau, S., Simard, S., Thung, S. N., Kral, J. G. 1999. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab, 84 (5), 1513-1517.
80. Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., Melchionda, N. 1999. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med., 107 (5), 450-455.
81. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M., Melchionda, N. 2001. Metformin in non-alcoholic steatohepatitis. Lancet, 358 (9285), 893-894.
82. Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., Rizzetto, M. 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37 (4), 917-923.
83. Matsuda, M., Korn, B. S., Hammer, R. E., Moon, Y. A., Komuro, R., Horton, J. D., Goldstein, J. L., Brown, M. S., Shimomura, I. 2001. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev., 15 (10), 1206-1216.
84. Matteoni, C. A., Younossi, Z. M., Gramlich, T., Boparai, N., Liu, Y. C., McCullough, A. J. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116 (6), 1413-1419.
85. Mavrelis, P. G., Ammon, H. V., Gleysteen, J. J., Komorowski, R. A., Charaf, U. K. 1983. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology, 3 (2), 226-231.
86. McGarry, J. D., Foster, D. W. 1980. Effects of exogenous fatty acid concentration on glucagon-induced changes in hepatic fatty acid metabolism. Diabetes, 29 (3), 236-240.
87. Mitchell, D. G. 1992. Focal manifestations of diffuse liver disease at MR imaging. Radiology, 185 (1), 1-11.
88. Mohr, S., Zech, B., Lapetina, E. G., Brune, B. 1997. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem. Biophys. Res. Commun., 238 (2), 387-391.
89. Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H. Jr., Perrillo, R. P. 2004. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther., 20 (1), 23-28.
90. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., Bacon, B. R. 2003a. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 38 (4), 1008-1017.
91. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Sponseller, C. A., Hampton, K., Bacon, B. R. 2003b. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol., 38 (4), 434-440.
92. Noer, H. M. 2002. History of hepatitis and liver disease in Indonesia. J. Gastroenterol. Hepatol, 17, S508-S509.
93. Okan, A., Astarcioglu, H., Tankurt, E., Sagol, O., Altekin, E., Astarcioglu, I., Gonen, O. 2002. Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig. Dis. Sci., 47 (11), 2389-2397.
94. Omagari, K., Kadokawa, Y., Masuda, J., Egawa, I., Sawa, T., Hazama, H., Ohba, K., Isomoto, H., Mizuta, Y., Hayashida, K., Murase, K., Kadota, T., Murata, I., Kohno, S. 2002. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol., 17 (10), 1098-1105.
95. Osada, S., Tsukamoto, T., Osumi, T. 1996. Analysis of the essential sequence elements in the peroxisome proliferator-responsive enhancer of rat acyl-CoA oxidase gene. Ann. N. Y. Acad. Sci., 804, 706-708.
96. Oshibuchi, M., Nishi, F., Sato, M., Ohtake, H., Okuda, K. 1991. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J. Gastroenterol. Hepatol., 6 (2), 165-168.
97. Pagano, G., Pacini, G., Musso, G., Gambino, R., Mecca, F., Depetris, N., Cassader, M., David, E., Cavallo-Perin, P., Rizzetto, M. 2002. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology, 35 (2), 367-372.
98. Pamuk, G. E., Sonsuz, A. 2003. N-Acetylcysteine in the treatment of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 18 (10), 1220-1221.
99. Piao, Y. F., Li, J. T., Shi, Y. 2003. Relationship between genetic polymorphism of cytochrome P4501IE1 and fatty liver. World J. Gastroenterol., 9 (11), 2612-2615.
100. Pinto, H. C., Baptista, A., Camilo, M. E., Valente, A., Saragoca, A., de Moura, M. C. 1996. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig. Dis. Sci., 41 (1), 172-179.
101. Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T. J., Yanovski, J. A., Kleiner, D. E., Hoofnagle, J. H. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 39 (1), 188-196.
102. Rai, R. M., Lee, F. Y., Rosen, A., Yang, S. Q., Lin, H. Z., Koteish, A., Liew, F. Y., Zaragoza, C., Lowenstein, C., Diehl, A. M. 1998. Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. Proc. Natl. Acad. Sci. USA, 95 (23), 13829-13834.
103. Rashid, M., Roberts, E. A. 2000. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr., 30 (1), 48-53.
104. Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Khalil, L., Turpin, G., Opolon, P., Poynard, T. 2000. Liver fibrosis in overweight patients. Gastroenterology, 118 (6), 1117-1123.
105. Reynet, C., Kahn, C. R. 1993. Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. Science, 262 (5138), 1441-1444.
106. Robertson, G., Leclercq, I., Farrell, G. C. 2001. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol Gastrointest. Liver Physiol., 281 (5), G1135-G1139.
107. Rozental, P., Biava, C., Spencer, H., Zimmerman, H. J. 1967. Liver morphology and function tests in obesity and during total starvation. Am. J. Dig. Dis., 12 (2), 198-208.
108. Sakakura, Y., Shimano, H., Sone, H., Takahashi, A., Inoue, N., Toyoshima, H., Suzuki, S., Yamada, N. 2001. Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem. Biophys. Res. Commun., 286 (1), 176-183.
109. Santos, V. N., Lanzoni, V. P., Szejnfeld, J., Shigueoka, D., Parise, E. R. 2003. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz. J. Med. Biol. Res., 36 (6), 723-729.
110. Sanyal, A. J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., Clore, J. N. 2001. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 120 (5), 1183-1192.
111. Schattenberg, J. M., Wang, Y., Rigoli, R. M., Koop, D. R., Czaja, M. J. 2004. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology, 39 (2), 444-455.
112. Scheen, A. J., Luyckx, F. H. 2003. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Acta Clin. Belg., 58 (2), 81-91.
113. Shertzer, H. G., Clay, C. D., Genter, M. B., Schneider, S. N., Nebert, D. W., Dalton, T. P. 2004. Cyp1a2 protects against reactive oxygen production in mouse liver microsomes. Free Rad. Biol. Med., 36 (5), 605-617.
114. Sheth, S. G., Gordon, F. D., Chopra, S. 1997. Nonalcoholic steatohepatitis. Ann. Intern. Med, 126 (2), 137-145.
115. Shimano, H. 2001. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog. Lipid Res., 40 (6), 439-452.
116. Shimomura, I., Bashmakov, Y., Horton, J. D. 1999. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem., 274 (42), 30028-30032.
117. Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., Goldstein, J. L. 1999. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA, 96 (24), 13656-13661.
118. Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S., Goldstein, J. L. 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell., 6 (1), 77-86.
119. Solomon, S. S., Mishra, S. K., Cwik, C., Rajanna, B., Postlethwaite, A. E. 1997. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm. Metab. Res., 29 (8), 379-382.
120. Starkel, P., Sempoux, C., Leclercq, I., Herin, M., Deby, C., Desager, J. P., Horsmans, Y. 2003. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J. Hepatol., 39 (4), 538-546.
121. Stone, B. G., Van Thiel, D. H. 1985. Diabetes mellitus and the liver. Semin. Liver Dis, 5 (1), 8-28.
122. Tapiero, H., Townsend, D. M., Tew, K. D. 2004. The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother., 58 (2), 100-110.
123. Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N., Woodyatt, N. J. 1996. Peroxisome proliferator-activated receptors: structures and function. Ann. N. Y. Acad. Sci, 804, 252-265.
124. Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., Tanikawa, K. 1997. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol., 27 (1), 103-107.
125. Uygun, A., Kadayifci, A., Isik, A. T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M., Dagalp, K. 2004. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 19 (5), 537-544.
126. Van der Meide, P. H., Schellekens, H. 1996. Cytokines and the immune response. Biotherapy, 8 (34), 243-249.
127. Videla, L. A., Rodrigo, R., Orellana, M., Fernandez, V., Tapia, G., Quinones, L., Varela, N., Contreras, J., Lazarte, R., Csendes, A., Rojas, J., Maluenda, F., Burdiles, P., Diaz, J. C., Smok, G., Thielemann, L., Poniachik, J. 2004. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (London), 106 (3), 261-268.
128. Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., Gorski, J. C. 2003. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br. J. Clin. Pharmacol., 55 (1), 77-85.
129. Wanless, I. R., Lentz, J. S. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology, 12 (5), 1106-1110.
130. Wu, C. C., Sheen, L. Y., Chen, H. W., Tsai, S. J., Lii, C. K. 2001. Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells. Food Chem. Toxicol., 39 (6), 563-569.
131. Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S., Cooper, G. J. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest, 112 (1), 91-100.
132. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., Kadowaki, T. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med, 7 (8), 941-946.
133. Yang, S. Q., Lin, H. Z., Lane, M. D., Clemens, M., Diehl, A. M. 1997. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA, 94 (6), 2557-2562.
134. Ylonen, K., Alfthan, G., Groop, L., Saloranta, C., Aro, A., Virtanen, S. M. 2003. Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am. J. Clin. Nutr, 77 (6), 1434-1441.
135. Younossi, Z. M., Diehl, A. M., Ong, J. P. 2002. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology, 35 (4), 746-752.
136. Younossi, Z. M., Gramlich, T., Bacon, B. R., Matteoni, C. A., Boparai, N., O'Neill, R., McCullough, A. J. 1999. Hepatic iron and nonalcoholic fatty liver disease. Hepatology, 30 (4), 847-850.
137. Zamin, I. Jr., de Mattos, A. A., Zettler, C. G. 2002. Nonalcoholic steatohepatitis in nondiabetic obese patients. Can. J. Gastroenterol., 16 (5), 303-307.
138. Zhang, J., Phillips, D. I., Wang, C., Byrne, C. D. 2004. Human skeletal muscle PPARalpha expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity. Am. J. Physiol. Endocrinol. Metab., 286 (2), E168-E175.
139. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., Moller, D. E. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 108 (8), 1167-1174.
140. Zimmerman, H. J., MacMurray, F. G., Rappaport, H., Alpert, L. K. 1950. Studies on the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin sensitivity. J. Lab. Clin. Med., 36 (6), 922-928.